YAYang Joon An

Yang Joon An

*This is an algorithmically generated author record based on publicly available information.

Yang Joon An has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prunus mume Extract Cooperates with Cisplatin to Induce Melanoma Apoptosis and Regulate Immune Responses

    by Je Hyoung Kim, Gyu Yeon Oh, Eun Hee Kim, Hee Yeon Lee, Eun Jin Yang, Hye Young Park, Sook Park, Yang Jun An, Jin Young Kim

    This study investigated the potential of Prunus mume (P. mume) extract as an anticancer adjuvant by evaluating its direct apoptotic effects on A375P human melanoma cells and its immunomodulatory impact on peripheral blood mononuclear cells (PBMCs). Furthermore, the extract demonstrated additive and chemosensitizing effects when combined with a sub-toxic dose of cisplatin, significantly enhancing the growth inhibition of A375P cells. Selective growth inhibition was confirmed using crystal violet assays, where the 80% ethanol (EtOH) extract exhibited significant dose-dependent inhibition of A375P viability while leaving human adult low-calcium high-temperature keratinocytes (HaCaT) largely unaffected. Apoptotic cell death was characterized by DNA fragmentation and disrupted mitochondrial membrane potential, which decreased to 77.3% of the control as evidenced by JC-1 staining. At the molecular level, quantitative real-time reverse transcription–polymerase chain reaction (RT-qPCR) analysis demonstrated the upregulation of pro-apoptotic markers, including Bax (2.08-fold at 30 h) and Caspase-3 (2.12-fold in 16 h floating cells), alongside significant downregulation of the anti-apoptotic gene Bcl-2 (down to 0.10-fold at 16 h adherent cells). Notably, initiator Caspase-9 expression was suppressed in co-treated cells, suggesting late-stage transcriptional attenuation during sustained drug exposure. The extract suppressed the NF-κB pathway and reduced PD-L1 mRNA levels by 2.63-fold (compared to 3.55-fold with cisplatin alone), suggesting a mechanism to mitigate chemo-induced inflammatory stress and immune dysregulation. Furthermore, while cisplatin induced an excessive inflammatory response in PBMCs, co-treatment with the extract normalized the cytokine profile by modulating IFN-γ (2.21-fold), TNF-α (3.37-fold), and IL-2 (1.60-fold) back toward baseline levels. The attenuation of cytotoxic effectors, Granzyme B (1.16-fold) and Perforin (0.73-fold), along with the costimulatory molecule CD80 (4.44-fold), suggests the modulation of excessive inflammatory activation and attenuation of immune hyper-responsiveness. Finally, biomolecular docking predictions using the Boltz-2 framework (an open-source biomolecular interaction prediction model) demonstrated high-affinity binding between key plum constituents (e.g., chlorogenic acid, citric acid) and target proteins such as Caspase-3, Bcl-2, Nrf2, and Keap1, providing a structural basis for their bioactivity. In conclusion, P. mume extract (PME) serves as a promising multi-target adjuvant that simultaneously triggers cancer cell apoptosis while mitigating cisplatin-induced inflammatory perturbations in immune cells.

  • Open Access

    Genomic Insights into Antimicrobial Resistance and Virulence of Monophasic Salmonella enterica I 4,[5],12:i:- Isolates from Clinical and Environmental Sources in Jeollanam-do, Korea

    by Eunbyeul Go, Bo Ra Kang, Hye Young Na, Hyung Woo Lim, Hye Lin Yang, Mi Young Shin, Yang Joon An, Sook Park, Ki-Bok Yoon

    This study investigated the molecular epidemiology, virulence, antimicrobial resistance, and mobile genetic elements (MGEs) of Salmonella enterica serovar I 4,[5],12:i:- isolates collected in Jeollanam-do, South Korea, between 2021 and 2023. A total of 135 isolates were tested for antimicrobial susceptibility and 14 virulence-associated genes were screened by PCR. Pulsed-field gel electrophoresis (PFGE) assessed clonal relatedness, and whole-genome sequencing (WGS) enabled multilocus sequence typing (MLST), core genome MLST (cgMLST), SNP phylogeny, resistance gene detection, and MGE analysis. Nine virulence profiles (VP1–VP9) were identified. VP1 (74.1%) was strongly associated with multidrug resistance (MDR), while VP2 (14.8%), which carried plasmid-encoded spv genes, remained largely susceptible. Overall, 83.7% of isolates were resistant to at least one antimicrobial, and 65.2% were MDR, with ampicillin and tetracycline consistently forming the backbone of MDR phenotypes. PFGE revealed high genetic diversity, with 72 pulsotypes, yet certain clones (e.g., SMOX01.006, SMOX01.012) were widely distributed and corresponded to VP2 isolates. WGS confirmed two dominant sequence types, ST34 (n = 24) and ST19 (n = 20), with SNP phylogeny showing VP1 isolates mainly clustered with ST34 and VP2 with ST19. Genotype–phenotype concordance showed strong agreement for most antimicrobials, except cefoxitin, ciprofloxacin, amikacin, and trimethoprim/sulfamethoxazole. MGE analysis revealed that tet(B) was consistently associated with ISVsa5, while ISEc59 was linked to multiple resistance genes, though only aac(3)-IV was phenotypically expressed. These findings demonstrate that MDR and virulence gene composition were closely associated with clonal clustering and that MGEs may contribute to resistance gene expression. This study provides a basis for understanding the dissemination of resistant and virulent Salmonella in the region and underscores the need for continuous genomic surveillance.